Saturday, September 23, 2023
Saturday, September 23, 2023

Philips Extends its Mobile C-arm Range with Zenition 30, Alleviating Staff Shortages by Empowering Surgeons with Greater Personalization and Control

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Image Guided Therapy Mobile C-arm System 3000 – Zenition 30 [1], the latest addition to the company’s highly versatile Zenition mobile C-arm series. Mobile C-arms are X-ray systems that are brought into the operating room (OR) to provide live image guidance during a wide range of clinical procedures which include orthopedics, trauma, spine, pain management and other surgical procedures.

The Zenition 30 gives surgeons a greater level of control, empowering them to work more autonomously and independently. By reducing dependency on support staff, Zenition 30 helps alleviate the staff shortages faced by many hospitals, while its workflow-enhancing features and excellent image quality allow surgeons to deliver high-quality care to more patients. The launch of the Zenition 30 follows the recent launch of the Philips Zenition 10 C-arm [2].

“Based on our Zenition platform’s proven ease of use and workflow efficiency, the new Zenition 30 offers a unique combination of personalized control and image clarity to enhance the speed and accuracy of decision-making for a range of clinical procedures at a price point that meets today’s economic and business goals,” said Mark Stoffels, General Manager, Philips Image Guided Therapy Systems.

High-quality imaging

Zenition 30 offers versatility for a range of clinical procedures which include orthopedics, trauma, spine, pain management and other surgical procedures. Featuring Philips’ latest-generation flat detector technology, advanced imaging algorithms, and personalized user profiles, the new system delivers superior image quality, dose efficiency, and workflow customization. From the moment a surgeon logs on, the Zenition 30 automatically adjusts to their preferred settings and way of working, contributing to fewer manual adjustments and more first-time-right imaging. In addition to rapid set-up and protocol selection, the Zenition 30 also offers surgeons much greater control over C-arm positioning during surgical procedures.

In independent usability studies involving clinicians around the world who were offered hands-on experience of the Zenition 30 in simulated environments, 95% said they believed its enhanced surgeon control would allow them to work independently [3], while 84% believed that Zenition 30’s personalized image quality profiles meant fewer images might be needed during a procedure because the first image already incorporates their preferred settings [4].

As part of its commitment to doing business sustainably and helping its customers make responsible choices, Philips has designed the Zenition 30 to have a 25% increased product lifetime [5] and also has a refurbished program available, making it ‘circular-ready’ for repair, refurbishment, and recycling [5].

Other C-arm systems in Philips’ Zenition series are the Zenition 50, Zenition 70, and the recently launched Zenition 10 [2].

[1] Zenition 30 mobile C-arm systems are available for sale in a limited number of countries. Please check with a local representative for availability in your market. Pending 510 (k) not available for sale in the USA.
[2] Zenition 10 mobile C-arm system is not available in the USA.
[3] Results were obtained during a claims substantiation study performed in February and September 2022 by Use-Lab GmbH, an independent company. Response is based on 37 clinicians around the world, who answered a questionnaire subsequent to a usability study with additional hands-on time with the system.
[4] Results were obtained during a claims substantiation study performed in February and September 2022 by Use-Lab GmbH, an independent company. Response is based on 50 clinicians around the world, who answered a questionnaire subsequent to a usability study with additional hands-on time with the system.

[5] Compared to its predecessor, BV Endura 2.3.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase...

The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy. An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis. The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients with la/mUC.

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

"Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "Based on the pre-clinical and clinical evidence generated to date, DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control, and was shown to be well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a disease with no current treatment options. The two-part design of this trial provides optionality for a potential interim analysis in the first half of 2024 and we expect to report the full data in the second half of 2024."

Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech

The "U.S. Market Gateway Accelerator for BioSciences and MedTech", sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market.

Karger Publishers New Journal – Immune System

“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann."

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Robert Barrow, Chief Executive Officer and Director of MindMed. “Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enroll almost 200 participants in this trial in just over a year. We anticipate sharing topline results during the fourth quarter of this year.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy